Australia markets closed

Onward Medical N.V. (63E.F)

Frankfurt - Frankfurt Delayed price. Currency in EUR
Add to watchlist
4.8600-0.3000 (-5.81%)
At close: 03:29PM CEST
Full screen
Previous close5.1600
Open5.0400
Bid4.9400 x N/A
Ask5.4600 x N/A
Day's range4.8100 - 5.0400
52-week range1.9950 - 6.5400
Volume100
Avg. volume180
Market cap180.07M
Beta (5Y monthly)0.79
PE ratio (TTM)N/A
EPS (TTM)N/A
Earnings dateN/A
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • GlobeNewswire

    ONWARD® Medical Reports Q1 2024 Update and Year-to-Date Highlights

    Nature Medicine published Up-LIFT pivotal trial results Submitted FDA De Novo application for ARC-EX® System Successfully raised EUR 20M in equity capital EINDHOVEN, the Netherlands, May 23, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), a medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today provided a Q1 2024 business update. “This week’s publication of Up-L

  • GlobeNewswire

    ONWARD® Medical to Host Webcast to Share Details from its Up-LIFT Trial and Yesterday’s Nature Medicine Publication

    Nature Medicine published Up-LIFT pivotal trial results Company will discuss pivotal trial results during webcast this week with company leaders and study principal investigators and participants EINDHOVEN, the Netherlands, May 21, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function, and independence in people with spinal cord injury (SCI), today announces that on Thursda

  • GlobeNewswire

    Nature Medicine Highlights Significant Improvement in Hand and Arm Function After Spinal Cord Injury with Use of ONWARD® ARC-EX® Therapy

    ARC Therapy™ shown to be safe and effective in global pivotal trial* 90% of participants improved either strength or function of upper limbs* Improvement demonstrated in participants up to 34 years post-injury* 87% of participants also reported improvement in overall quality of life* EINDHOVEN, the Netherlands, May 20, 2024 (GLOBE NEWSWIRE) -- ONWARD Medical N.V. (Euronext: ONWD), the medical technology company creating innovative spinal cord stimulation therapies to restore movement, function,